ArticleCureus2025
Monkeypox-Related Ocular Disease: Disciform Keratitis and Recurrent Keratouveitis in an Immunocompetent Patient in a Resource-Limited Setting.
Article in Cureus, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
1 citing paper in PubMed.
- Recent advances in Mpox across innate immunity, evasion, and clinical outcomes.Communications biology · 2026Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
2 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Monkeypox-related ocular disease (MPXROD) is an uncommon but potentially sight-threatening complication of monkeypox virus (MPXV) infection. While most cases improve with supportive care, some patients may develop ocular involvement. We describe a 28-year-old immunocompetent man who experienced decreased vision and paracentral dendritic corneal ulcers during the acute phase of infection. Initial treatment, directed at presumed herpetic keratitis, successfully resolved the ulcers but left a residual stromal leukoma. Subsequent inflammatory flares led to an anterior chamber paracentesis, which confirmed MPXV as the causative agent. Since first-line antiviral options were not available, therapy was adjusted to oral valaciclovir alongside tapering corticosteroids. Recurrent episodes of keratouveitis were effectively managed with repeated courses of antivirals, corticosteroids, and ocular lubricants, as well as the addition of compounded topical insulin. This case highlights that MPXROD can lead to recurrent keratouveitis even in otherwise healthy individuals. When first-line antivirals are not available, treatment must be individualized, combining antivirals, corticosteroids, supportive care, and adjunctive therapies, such as topical insulin, which can play a crucial role in preserving vision and healing corneal damage in recurrent flares.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.